DEFINITION
What is Mistletoe ?
European mistletoe (Viscum album L.) is a hemiparasitic plant used in integrative oncology as a supportive treatment, not a curative one, alongside conventional cancer care. It's distinct from American mistletoe, and it's easy to confuse the two.
Mistletoe extracts contain active compounds called lectins and viscotoxins. Lab and animal studies have shown immune-stimulating and anti-tumor activity from these compounds. The strongest and most consistent finding in clinical studies, though, is an improvement in quality of life for patients undergoing cancer treatment.
Mistletoe therapy is not an alternative to conventional oncology, and we don't treat it as one. At GWCIM, it's offered as a complement to chemotherapy, radiation, surgery, or immunotherapy.
Qualifications & Background
Mistletoe therapy at GWCIM is prescribed and supervised by medical doctors and licensed naturopathic physicians trained in integrative oncology. Every patient completes a formal medical intake, and we monitor progress with regular lab work throughout treatment.
INDICATIONS
What conditions does it help with?
ADVANTAGE
Why Mistletoe at GWCIM?
GWCIM has offered mistletoe therapy as part of its integrative oncology program since the center's early years. Our naturopathic physicians know how to match preparation and dosing to your cancer type, treatment history, and current health. You're also plugged into GWCIM's broader team while you're here (physicians, nutritionists, mental health providers), so if something else comes up during treatment, someone is already looped in.
APPROACH
Our Process
Every patient starts with a thorough consultation to review their oncology history, current treatment plan, and recent lab work. That assessment determines whether mistletoe therapy makes sense, and if it does, which preparation and dosing approach fits your situation.
Mistletoe therapy has been studied mainly in adults with solid tumor malignancies who are receiving active conventional treatment or best supportive care. Clinical evidence supports a role in improving quality of life for patients with:
- Non-small cell lung cancer
- Breast cancer
- Ovarian cancer
- Pancreatic cancer
We may also consider it for patients who've finished active treatment and are focused on recovery and long-term wellbeing. Suitability gets determined individually at consultation.
Most patients learn to self-administer mistletoe at home on a schedule set by their provider. Everyone on mistletoe therapy sees their GWCIM physician about once a month for reassessment, and we stay in touch with your oncology team as needed.
Care Options
Initial Mistletoe Consultation
Full oncology intake, laboratory review, eligibility assessment, and treatment planning with a GWCIM naturopathic physician.
Ongoing Treatment and Monitoring
Monthly follow-up appointments; laboratory monitoring as indicated; dose adjustments as needed.
In-Person Only
This service requires in-person visits at our Washington, DC clinic at 908 New Hampshire Ave NW, Suite 200.
EXPERTISE
Recommended Providers
LEARN MORE
What to expect as a patient
- Initial Consultation: A full intake with one of our naturopathic physicians to review your diagnosis, current treatment, medical history, and recent labs (a metabolic panel and complete blood count are required). This appointment determines eligibility and sets your treatment plan.
- Training: If you're a candidate for home self-administration, we'll train you on the technique before you start using it independently.
- Ongoing Monitoring: Follow-up appointments about once a month to check your response, review labs, and adjust dosing if needed.
- Coordination of Care: We stay in touch with your oncologist as appropriate. We won't recommend mistletoe therapy in isolation from your primary cancer care team.
EDUCATION
More About Mistletoe
Study References:
- Estko M et al. Tumour cell-derived effects on monocyte/macrophage polarization and function, and modulatory potential of Viscum album lipophilic extract in vitro. BMC Complementary and Alternative Medicine, 2015.
- Cebovic T et al. Cytotoxic effects of the Viscum album L. extract on Ehrlich tumour cells in vivo. Phytotherapy Research, 2008.
- Weissenstein U et al. Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro.
- Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients.
- Piao BK et al. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian, and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Research, 2004.
- Troger W et al. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe. Deutsches Ärzteblatt International, 2014.
- Troger W et al. Five-year follow-up of patients with early-stage breast cancer after a randomized study comparing additional treatment with Viscum album (L.) extract to chemotherapy alone.
FAQ
Common Questions
No. Mistletoe extracts aren't currently approved by the U.S. Food and Drug Administration for cancer or any other condition. They're available in the United States under a licensed physician's oversight, and clinical trials are ongoing. In Europe, mistletoe preparations have been used in oncology for over a century and are still widely prescribed there.
The most reliable clinical evidence supports mistletoe's potential to improve quality of life, specifically appetite, sleep, energy, and general wellbeing, in patients with certain cancers who are on conventional treatment. Evidence on tumor response, recurrence, or survival is less consistent and more limited methodologically. We'll walk you through where the research actually stands at your consultation.
The most common side effect is a local reaction at the application site: redness, mild swelling, or warmth. We generally consider that a sign of immune activation, not a problem. Mild flu-like symptoms (fatigue, low-grade fever) show up occasionally, especially early in treatment. Serious adverse events are rare when therapy is properly supervised and dosed, and we'll go over the full side-effect profile with you at your consultation.
EDUCATION